These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 31159615)

  • 21. Selection of potential iron oxide nanoparticles for breast cancer treatment based on in vitro cytotoxicity and cellular uptake.
    Poller JM; Zaloga J; Schreiber E; Unterweger H; Janko C; Radon P; Eberbeck D; Trahms L; Alexiou C; Friedrich RP
    Int J Nanomedicine; 2017; 12():3207-3220. PubMed ID: 28458541
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CircACAP2 promotes breast cancer proliferation and metastasis by targeting miR-29a/b-3p-COL5A1 axis.
    Zhao B; Song X; Guan H
    Life Sci; 2020 Mar; 244():117179. PubMed ID: 31863774
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of umbilical cord mesenchymal stem cell labeling with superparamagnetic iron oxide nanoparticles coated with dextran and complexed with Poly-L-lysine.
    Sibov TT; Miyaki LA; Mamani JB; Marti LC; Sardinha LR; Pavon LF; Oliveira DM; Cardenas WH; Gamarra LF
    Einstein (Sao Paulo); 2012; 10(2):180-8. PubMed ID: 23052453
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Different effect of hydrogelation on antifouling and circulation properties of dextran-iron oxide nanoparticles.
    Karmali PP; Chao Y; Park JH; Sailor MJ; Ruoslahti E; Esener SC; Simberg D
    Mol Pharm; 2012 Mar; 9(3):539-45. PubMed ID: 22243419
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Carboxymethyl dextran-trimethyl chitosan coated superparamagnetic iron oxide nanoparticles: An effective siRNA delivery system for HIV-1 Nef.
    Kamalzare S; Noormohammadi Z; Rahimi P; Atyabi F; Irani S; Tekie FSM; Mottaghitalab F
    J Cell Physiol; 2019 Nov; 234(11):20554-20565. PubMed ID: 31144311
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MiR-218 regulates cisplatin chemosensitivity in breast cancer by targeting BRCA1.
    He X; Xiao X; Dong L; Wan N; Zhou Z; Deng H; Zhang X
    Tumour Biol; 2015 Mar; 36(3):2065-75. PubMed ID: 25394901
    [TBL] [Abstract][Full Text] [Related]  

  • 27. miRNA-29a reverses P-glycoprotein-mediated drug resistance and inhibits proliferation via up-regulation of PTEN in colon cancer cells.
    Shi X; Valizadeh A; Mir SM; Asemi Z; Karimian A; Majidina M; Safa A; Yosefi B
    Eur J Pharmacol; 2020 Aug; 880():173138. PubMed ID: 32416187
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glutathione responsive chitosan-thiolated dextran conjugated miR-145 nanoparticles targeted with AS1411 aptamer for cancer treatment.
    Tekie FSM; Soleimani M; Zakerian A; Dinarvand M; Amini M; Dinarvand R; Arefian E; Atyabi F
    Carbohydr Polym; 2018 Dec; 201():131-140. PubMed ID: 30241804
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Determination of Dysregulated miRNA Expression Levels by qRT-PCR after the Application of Usnic Acid to Breast Cancer.
    Tanman Ü; Yangın S; Cansaran-Duman D
    Anticancer Agents Med Chem; 2020; 20(5):548-558. PubMed ID: 31549595
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tamoxifen differentially regulates miR-29b-1 and miR-29a expression depending on endocrine-sensitivity in breast cancer cells.
    Muluhngwi P; Krishna A; Vittitow SL; Napier JT; Richardson KM; Ellis M; Mott JL; Klinge CM
    Cancer Lett; 2017 Mar; 388():230-238. PubMed ID: 27986463
    [TBL] [Abstract][Full Text] [Related]  

  • 31. miRNA expression patterns in chemoresistant breast cancer tissues.
    Lv J; Xia K; Xu P; Sun E; Ma J; Gao S; Zhou Q; Zhang M; Wang F; Chen F; Zhou P; Fu Z; Xie H
    Biomed Pharmacother; 2014 Oct; 68(8):935-42. PubMed ID: 25451164
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic potential of anti-miR29a in breast cancer patients with type 2 diabetes: an
    Li Z; Min L; Chen L; Hu Y; Luan W; Li C; Xiong Q; Huang K
    Transl Cancer Res; 2022 May; 11(5):1285-1296. PubMed ID: 35706821
    [TBL] [Abstract][Full Text] [Related]  

  • 33. miRNA-205 targets VEGFA and FGF2 and regulates resistance to chemotherapeutics in breast cancer.
    Hu Y; Qiu Y; Yagüe E; Ji W; Liu J; Zhang J
    Cell Death Dis; 2016 Jun; 7(6):e2291. PubMed ID: 27362808
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MicroRNA-574 enhances doxorubicin resistance through down-regulating SMAD4 in breast cancer cells.
    Sun FD; Wang PC; Luan RL; Zou SH; Du X
    Eur Rev Med Pharmacol Sci; 2018 Mar; 22(5):1342-1350. PubMed ID: 29565492
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Formulation of Anti-miR-21 and 4-Hydroxytamoxifen Co-loaded Biodegradable Polymer Nanoparticles and Their Antiproliferative Effect on Breast Cancer Cells.
    Devulapally R; Sekar TV; Paulmurugan R
    Mol Pharm; 2015 Jun; 12(6):2080-92. PubMed ID: 25880495
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chromenone-conjugated magnetic iron oxide nanoparticles. Toward conveyable DNA binders.
    Yousuf S; Enoch IVMV; Paulraj MS; Dhanaraj P
    Colloids Surf B Biointerfaces; 2015 Nov; 135():448-457. PubMed ID: 26280819
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of silibinin-loaded nano-niosomal coated with trimethyl chitosan on miRNAs expression in 2D and 3D models of T47D breast cancer cell line.
    Yazdi Rouholamini SE; Moghassemi S; Maharat Z; Hakamivala A; Kashanian S; Omidfar K
    Artif Cells Nanomed Biotechnol; 2018 May; 46(3):524-535. PubMed ID: 28509572
    [TBL] [Abstract][Full Text] [Related]  

  • 38. miR-29a suppresses growth and metastasis in papillary thyroid carcinoma by targeting AKT3.
    Li R; Liu J; Li Q; Chen G; Yu X
    Tumour Biol; 2016 Mar; 37(3):3987-96. PubMed ID: 26482618
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of oleuropein on apoptotic pathway regulators in breast cancer cells.
    Asgharzade S; Sheikhshabani SH; Ghasempour E; Heidari R; Rahmati S; Mohammadi M; Jazaeri A; Amini-Farsani Z
    Eur J Pharmacol; 2020 Nov; 886():173509. PubMed ID: 32889065
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer.
    Deng X; Cao M; Zhang J; Hu K; Yin Z; Zhou Z; Xiao X; Yang Y; Sheng W; Wu Y; Zeng Y
    Biomaterials; 2014 May; 35(14):4333-44. PubMed ID: 24565525
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.